-
1
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
2
-
-
33847118123
-
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
-
DOI 10.1007/s00280-006-0393-4
-
Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574. (Pubitemid 46295136)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.59
, Issue.5
, pp. 561-574
-
-
Chang, Y.S.1
Adnane, J.2
Trail, P.A.3
Levy, J.4
Henderson, A.5
Xue, D.6
Bortolon, E.7
Ichetovkin, M.8
Chen, C.9
McNabola, A.10
Wilkie, D.11
Carter, C.A.12
Taylor, I.C.A.13
Lynch, M.14
Wilhelm, S.15
-
3
-
-
33644747449
-
BAY 43-9006 inhibition of oncogenic RET mutants
-
DOI 10.1093/jnci/djj069
-
Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326-334. (Pubitemid 43338212)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.5
, pp. 326-334
-
-
Carlomagno, F.1
Anaganti, S.2
Guida, T.3
Salvatore, G.4
Troncone, G.5
Wilhelm, S.M.6
Santoro, M.7
-
4
-
-
67650113975
-
Array of cutaneous adverse effects associated with sorafenib
-
Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61:360-361.
-
(2009)
J Am Acad Dermatol
, vol.61
, pp. 360-361
-
-
Kong, H.H.1
Turner, M.L.2
-
5
-
-
71949112710
-
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
-
Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
-
(2009)
Br J Dermatol
, vol.161
, Issue.5
, pp. 1045-1051
-
-
Lee, W.J.1
Lee, J.L.2
Chang, S.E.3
-
6
-
-
47849105015
-
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
-
DOI 10.1001/archderm.144.7.886
-
Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886-892. (Pubitemid 352039741)
-
(2008)
Archives of Dermatology
, vol.144
, Issue.7
, pp. 886-892
-
-
Autier, J.1
Escudier, B.2
Wechsler, J.3
Spatz, A.4
Robert, C.5
-
8
-
-
33845705260
-
Keratoacanthomas associated with sorafenib therapy
-
Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56:171-172.
-
(2007)
J Am Acad Dermatol
, vol.56
, pp. 171-172
-
-
Kong, H.H.1
Cowen, E.W.2
Azad, N.S.3
-
9
-
-
65249127575
-
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib
-
Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-23.
-
(2009)
Clin Genitourin Cancer
, vol.7
, pp. 20-23
-
-
Dubauskas, Z.1
Kunishige, J.2
Prieto, V.G.3
-
10
-
-
33749849376
-
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
-
DOI 10.1111/j.1365-2230.2006.02223.x
-
Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006;31:783-785. (Pubitemid 44563396)
-
(2006)
Clinical and Experimental Dermatology
, vol.31
, Issue.6
, pp. 783-785
-
-
Lacouture, M.E.1
Desai, A.2
Soltani, K.3
Petronic-Rosic, V.4
Laumann, A.E.5
Ratain, M.J.6
Stadler, W.M.7
-
11
-
-
47049127786
-
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
-
Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-5620.
-
(2008)
Blood
, vol.111
, pp. 5610-5620
-
-
Hipp, M.M.1
Hilf, N.2
Walter, S.3
-
12
-
-
0033762498
-
The EGF receptor: An essential regulator of multiple epidermal functions
-
Jost M, Kari C, Rodeck U. The EGF receptor: An essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505-510.
-
(2000)
Eur J Dermatol
, vol.10
, pp. 505-510
-
-
Jost, M.1
Kari, C.2
Rodeck, U.3
-
13
-
-
60549099595
-
Generalised erythematous skin eruptions induced by sorafenib: Cutaneous toxicity and treatment outcome
-
Galan Brotons A, Borras-Blasco J, Rosique-Robles JD, et al. Generalised erythematous skin eruptions induced by sorafenib: Cutaneous toxicity and treatment outcome. Clin Transl Oncol. 2008;10:844-846.
-
(2008)
Clin Transl Oncol
, vol.10
, pp. 844-846
-
-
Galan Brotons, A.1
Borras-Blasco, J.2
Rosique-Robles, J.D.3
|